Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists

Influenza Vaccination in Seniors Clinical Trial

Official title: Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists

Status Completed

Clinical Trial Summary

The application of the TLR7/8 (Toll Like Receptor) agonist gel (immune response helper) resiquimod will enhance the immune response to the intradermal influenza vaccine in seniors 65-75 years of age.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Influenza Vaccination in Seniors
• Influenza, Human

• NCT number: NCT01737580
• Study type: Interventional
• Source: University of British Columbia
• Status: Completed
• Phase: Phase 1
• Start date: April 2013
• Completion date: June 2013